Pentoxifylline has 30 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 10 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Ketorolac Tromethamine, Anti-Platelet Agents, Aspirin. Patients taking Pentoxifylline should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 30
- Contraindicated
- 1
- Major
- 10
- Moderate
- 19
Contraindicated (1)
- Pentoxifylline + Ketorolac Tromethamine— Concomitant use is contraindicated due to increased risk of bleeding.
Major (10)
- Pentoxifylline + Anti-Platelet Agents— Bleeding has been reported in patients treated with pentoxifylline with or without concomitant platelet aggregation inhi…
- Pentoxifylline + Aspirin— Bleeding has been reported in patients treated with pentoxifylline with or without concomitant NSAIDs.
- Pentoxifylline + Insulin Aspart Injection— May increase the risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
- Pentoxifylline + Insulin Degludec— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Pentoxifylline + Insulin Glargine— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Pentoxifylline + Insulin Glargine-Yfgn— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Pentoxifylline + Insulin Lispro— May increase the risk of hypoglycemia; dose adjustment and increased glucose monitoring required.
- Pentoxifylline + Oral Anticoagulants— Bleeding has been reported in patients treated with pentoxifylline with or without concomitant anticoagulants.
- Pentoxifylline + Theophylline— Concomitant administration leads to increased theophylline levels and theophylline toxicity in some individuals. Monitor…
- Pentoxifylline + Vitamin K Antagonists— Increased prothrombin time and increased anticoagulant activity reported. Monitoring of anticoagulant activity recommend…
Moderate (19)
- Pentoxifylline + Captopril— Small decreases in blood pressure observed in some patients. Periodic systemic blood pressure monitoring recommended.
- Pentoxifylline + Cimetidine— Increases average steady state plasma concentration of pentoxifylline (~25%) and Metabolite I (~30%).
- Pentoxifylline + Ciprofloxacin— Strong CYP1A2 inhibitor that may increase exposure to pentoxifylline.
- Pentoxifylline + Fluvoxamine— Strong CYP1A2 inhibitor that may increase exposure to pentoxifylline.
- Pentoxifylline + Glimepiride— May increase glucose-lowering effect of glimepiride, increasing susceptibility to and/or intensity of hypoglycemia.
- Pentoxifylline + Glipizide— May increase glucose-lowering effect of glipizide and susceptibility to hypoglycemia; monitor closely.
- Pentoxifylline + Insulin Aspart-Szjj— May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
- Pentoxifylline + Insulin Degludec And Liraglutide— May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.
- Pentoxifylline + Insulin Detemir— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Pentoxifylline + Insulin Glargine And Lixisenatide— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
- Pentoxifylline + Insulin Glargine-Aglr— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
- Pentoxifylline + Insulin Glulisine— May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
- Pentoxifylline + Insulin Human— May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.
- Pentoxifylline + Insulin Icodec-Abae— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
- Pentoxifylline + Insulin Lispro-Aabc— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
- Pentoxifylline + Nifedipine— Small decreases in blood pressure observed in some patients. Periodic systemic blood pressure monitoring recommended.
- Pentoxifylline + Pioglitazone And Glimepiride— May increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia. Close monitoring require…
- Pentoxifylline + Pramlintide Acetate— May increase susceptibility to hypoglycemia when coadministered with SYMLIN. Use with caution.
- Pentoxifylline + Repaglinide— May increase risk of hypoglycemia. Repaglinide dose reductions and increased glucose monitoring may be required.